Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 1 April 2008, Vol. 111, No. 7, pp. 3859-3862.
Prepublished online as a Blood First Edition Paper on January 22, 2008; DOI 10.1182/blood-2007-06-098251.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Figures
Right arrow All Versions of this Article:
blood-2007-06-098251v1
111/7/3859    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Google Scholar
Right arrow Articles by Sportoletti, P.
Right arrow Articles by Pandolfi, P. P.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sportoletti, P.
Right arrow Articles by Pandolfi, P. P.
Related Collections
Right arrow Oncogenes and Tumor Suppressors
Right arrow Brief Reports
Right arrow Neoplasia
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

NEOPLASIA

Brief Report

Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse

Paolo Sportoletti1,2,4, Silvia Grisendi1,2, Samia M. Majid1,2,4, Ke Cheng1,2,4, John G. Clohessy1,2,4, Agnes Viale3, Julie Teruya-Feldstein2, and Pier Paolo Pandolfi1,2,4

1 Cancer Biology and Genetics Program, 2 Department of Pathology, 3 Genomics Core Laboratory, Memorial Sloan-Kettering Cancer Center (MSKCC), New York, NY; and 4 Cancer Genetics Program, Beth Israel Deaconess Cancer Center and Department of Medicine, Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School, Boston, MA

Nucleophosmin (NPM1) gene has been heavily implicated in cancer pathogenesis both as a putative proto-oncogene and tumor suppressor gene. NPM1 is the most frequently mutated gene in acute myeloid leukemia (AML), while deletion of 5q, where NPM1 maps, is frequent in patients with myelodysplastic syndromes (MDS). We have previously shown that mice heterozygous for Npm1 (Npm1+/–) develop a hematologic syndrome with features of human MDS. Here we analyzed Npm1+/– mutants to determine their susceptibility to cancer. Npm1+/– mice displayed a greater propensity to develop malignancies compared with Npm1+/+ mice. The Npm1+/– cohort frequently developed hematologic malignancies of both myeloid and lymphoid origin with myeloid malignancies displaying the highest incidence. Malignant cells retained the wild-type allele with normal localization and expression of Npm1 at the protein level, suggesting that complete Npm1 loss is not a prerequisite for tumorigenesis. Our results conclusively demonstrate that Npm1 acts as a haploinsufficient tumor suppressor in the hematopoietic compartment.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




click for free articles
home about blood authors subscriptions permissions advertising public access contact us
Sponsor: Genentech BioOncology and and Biogen Idec
Blood Online is supported in part by
Genentech BioOncology and Biogen Idec
  Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020